Product Overview

Progesterone 100 mg Injection is a sterile, aqueous solution of micronized progesterone formulated for intramuscular administration. Each ampule or vial contains 100 mg of progesterone in a 1 ml or 2 ml volume, respectively, and is supplied by Sun Pharmaceutical Industries Ltd, a globally recognized manufacturer with a strong compliance record. The product is indicated for the treatment of female infertility associated with luteal phase deficiency and as part of hormone replacement therapy in selected clinical contexts. Pack size options include 5, 10, or 15 ampoules per carton, providing flexibility for clinical practices and patient adherence. The medication is shipped in temperature‑controlled packaging to preserve potency, with an estimated delivery window of 6 to 15 days from the date of order. Proper storage at 15‑30 °C protects the active ingredient from degradation, ensuring consistent therapeutic efficacy.

What is Progesterone 100 mg Injection?

Progesterone is a steroid hormone that prepares the endometrium for implantation and maintains early pregnancy. In pharmaceutical form, the 100 mg injection delivers a calibrated dose of the hormone directly into systemic circulation, bypassing the first‑pass hepatic metabolism that characterizes oral formulations. The generic version contains the same active molecule as branded products, meeting United States Pharmacopeia (USP) standards for identity, strength, purity, and potency. Clinically, the injection is used to supplement deficient luteal phase activity, support assisted reproductive technologies such as in‑vitro fertilization, and as an adjunct in hormone replacement regimens for menopausal symptom management. Its pharmacokinetic profile features a rapid peak concentration within hours, followed by a half‑life of approximately 12–16 hours, allowing flexible dosing schedules under medical supervision.

Uses and Benefits

The therapeutic benefits of Progesterone 100 mg Injection extend across reproductive endocrinology and menopausal health. In assisted reproduction, luteal phase support with progesterone improves implantation rates and reduces miscarriage risk, as demonstrated in multiple randomized controlled trials indexed in PubMed. For women experiencing hormonal imbalance, the injection offers a reliable route to restore progesterone levels when oral or transdermal options are unsuitable due to gastrointestinal intolerance or poor absorption. In hormone replacement therapy, progesterone counters estrogen‑driven endometrial proliferation, thereby lowering the incidence of endometrial hyperplasia and carcinoma. Patients often report improved menstrual regularity, reduced hot flashes, and better sleep quality when the medication is incorporated into a comprehensive treatment plan. The product’s standardized dosing eliminates variability between batches, supporting consistent clinical outcomes.

How It Works

Progesterone exerts its biological effects by binding to intracellular progesterone receptors (PGR), which act as transcription factors to modulate gene expression in target tissues. In the uterus, this results in secretory transformation of the endometrium, creating a receptive environment for blastocyst attachment. In the ovary, progesterone provides negative feedback to the hypothalamic‑pituitary axis, regulating luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) secretion, which is essential for maintaining corpus luteum function. The injected formulation delivers a physiologic dose that mimics the natural hormone, ensuring appropriate receptor activation without excessive systemic exposure. This mechanism underlies its role in supporting early pregnancy and mitigating symptoms associated with estrogen dominance, such as endometrial thickening and abnormal bleeding.

Dosage Guidelines

Administration of Progesterone 100 mg Injection must be individualized by a qualified healthcare professional based on the patient’s clinical status, concomitant therapies, and laboratory monitoring. Typical regimens for luteal phase support involve a single 100 mg intramuscular dose administered every 48–72 hours until a pregnancy test is performed, while longer‑term hormone replacement protocols may involve weekly or bi‑weekly injections depending on the therapeutic goal. The medication is supplied as a single‑use ampule or vial; the stopper should be disinfected with an alcohol swab before puncture, and the entire contents should be injected into a deep gluteal muscle to minimize vascular injury. Patients should be instructed to rotate injection sites and avoid reuse of needles. Dosage adjustments are recommended in patients with hepatic impairment or those receiving strong enzyme‑inducing drugs, and concomitant use of anticoagulants requires careful monitoring for bleeding risk.

Side Effects

Like all hormonal medications, Progesterone 100 mg Injection can produce adverse effects, although most are mild and transient. Common side effects include injection site pain, erythema, or induration, as well as bloating, breast tenderness, and mild mood changes. Less frequently, patients may experience headache, dizziness, or temporary fluid retention. Rare but serious reactions such as thromboembolic events, severe allergic dermatitis, or ovarian hyperstimulation syndrome require immediate medical attention. The United States Food and Drug Administration (FDA) advises clinicians to counsel patients about the signs of venous thromboembolism, especially when progesterone is used in combination with estrogen therapy. For a comprehensive list of reported reactions, refer to the Drugs.com side‑effect database, which aggregates post‑marketing surveillance data.

Warnings and Precautions

Progesterone 100 mg Injection is contraindicated in individuals with known hypersensitivity to the product, active or suspected hormone‑sensitive cancers, and severe hepatic disease. It should not be administered to pregnant women unless prescribed for specific therapeutic indications, and caution is advised during lactation due to potential transfer into breast milk. Drug interactions may alter progesterone metabolism; therefore, concomitant use of strong CYP3A4 inducers such as rifampin or anticonvulsants like carbamazepine may diminish therapeutic efficacy. Patients with a history of thromboembolic disorders should undergo regular screening, and baseline lipid profiles are recommended for long‑term hormone replacement users. Storage instructions stipulate that the product be kept in its original packaging at controlled room temperature and discarded after the expiration date printed on each ampule or vial. For detailed prescribing information, consult the FDA drugs portal or the Wikipedia progesterone page.

Frequently Asked Questions

1. How often should I receive the injection? Typically every 48–72 hours for luteal support, but the exact schedule is individualized by your clinician.
2. Can I use this product if I am already pregnant? It is generally intended for specific therapeutic purposes under medical supervision; self‑administration without a prescription is not recommended.
3. Is the injection painful? Most patients experience mild discomfort at the injection site; using a fine needle and rotating sites can reduce pain.
4. Do I need to monitor my hormone levels? Yes, clinicians often check serum progesterone and related hormones to ensure the therapy remains within the therapeutic range.
5. Where can I find more information about progesterone therapy? Trusted sources include the NIH overview of progesterone, MedlinePlus, and the references above.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)